Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4094207 | 0.84 | MEN1 (0.53) | ALDH1A1MEN1KMT2ACA2CA9 | |
| SCHEMBL13558569 | 0.78 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2ACA12CA2 | |
| SCHEMBL13558118 | 0.74 | MEN1 (0.50) | ALDH1A1MEN1KMT2ACA2CA9 | |
| SCHEMBL598551 | 0.69 | ALDH1A1 (0.77) | ALDH1A1MEN1KMT2ACA12CA2 | |
| SCHEMBL8199849 | 0.67 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2ACA12CA2 | |
| SCHEMBL2015532 | 0.67 | ALDH1A1 (0.74) | ALDH1A1MEN1KMT2ACA12CA2 | |
| SCHEMBL6355304 | 0.66 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2ACA12CA2 | |
| SCHEMBL12629636 | 0.66 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2ACA12CA2 | |
| SCHEMBL4581466 | 0.66 | ALDH1A1 (0.71) | ALDH1A1MEN1KMT2ACA12CA2 | |
| SCHEMBL6130639 | 0.66 | CA12 (0.81) | ALDH1A1MEN1KMT2ACA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | Nordion (Canada) Inc (CA) | 2012-11-01 | — | — | US | disclosed |
| US-8198101-B2 | Bifunctional polyazamacrocyclic chelating agents | NORDION (CANADA) INC. (CA) | 2012-06-12 | — | — | US | disclosed |
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | MDS (CANADA) INC. (CA) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202521-A1 | Bifunctional Polyazamacrocyclic Chelating Agents | LPXN, FCGRT, POLQ | ALDH1A1 2764/4885MEN1 691/4885KMT2A 900/4885 |
| US-20120276001-A1 | BIFUNCTIONAL POLYAZAMACROCYCLIC CHELATING AGENTS | LPXN, FCGRT, F13A1 | ALDH1A1 2824/4885MEN1 497/4885KMT2A 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.